FDA Blocks Publication of Studies Confirming COVID

What Did the FDA Studies Actually Find?

According to The BMJ's reporting, FDA scientists conducted post-authorization safety analyses on both mRNA COVID-19 vaccines and the recombinant shingles vaccine Shingrix. Both analyses reportedly supported the existing safety profile of these products, finding no new or unexpected serious adverse events at the population level. These types of studies are routine for the agency and typically feed into ongoing benefit-risk assessments shared with the medical community.

The shingles vaccine, in particular, has been the subject of public debate after isolated reports of inflammatory reactions in older adults. The FDA analysis, sources told BMJ, did not identify a causal link between the vaccine and the conditions in question. Similar reassurance emerged from the COVID-19 analysis, which examined large datasets including the agency's BEST initiative and Vaccine Adverse Event Reporting System data.

Why Is Suppressing Safety Data So Controversial?

Vaccine policy historically relies on open scientific discourse. When regulatory agencies publish reassuring safety data, that information helps clinicians counsel hesitant patients and gives independent researchers material to scrutinize. Conversely, when an agency holds back favorable findings, it can fuel conspiracy theories suggesting the data must be unfavorable — even when the opposite is true.

The BMJ report comes amid a broader political shift in US health agencies that has seen vaccine advisory committees restructured and longstanding immunization recommendations questioned. Critics warn that selective release of evidence, regardless of intent, erodes the credibility of regulators worldwide. The World Health Organization and major medical societies have repeatedly emphasized that transparent communication of safety surveillance is essential to maintaining trust in public health programs.

What Are the Implications for Patients and Clinicians?

Despite the controversy, the underlying scientific consensus on these vaccines has not changed. Multiple independent studies published in The Lancet, JAMA, and the New England Journal of Medicine have demonstrated favorable safety profiles for both mRNA COVID-19 vaccines and Shingrix. The CDC's Advisory Committee on Immunization Practices continues to recommend shingles vaccination for adults aged 50 and older, and COVID-19 boosters remain recommended for high-risk groups.

For patients, the practical guidance is unchanged: the established benefits of both vaccines — preventing severe COVID-19 illness and post-herpetic neuralgia from shingles — continue to outweigh known risks. The deeper concern raised by The BMJ report is institutional. Restoring confidence in regulatory science may require formal commitments to publish all completed safety analyses, regardless of whether findings align with current political narratives.